GlaxoSmithKline/£GSK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About GlaxoSmithKline

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

£GSK
Sector

Primary listing

LSE

Employees

68,629

GlaxoSmithKline Metrics

BasicAdvanced
£58B
17.51
£0.83
0.27
£0.62
4.28%

What the Analysts think about GlaxoSmithKline

Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.

Bulls say / Bears say

GSK expects full-year 2025 sales and profit at the top end of its 3–5% revenue growth and 6–8% EPS guidance after reporting Q2 sales of £7.99 billion and adjusted EPS of 46.5 pence, both beating analyst forecasts (Reuters)
The £2 billion share buyback launched after Q4 2024 results, combined with a revised long-term sales target near $50 billion, underscores management’s confidence in GSK’s growth drivers (Reuters)
U.S. CDC’s July 2025 acceptance of ACIP recommendations expanded use of GSK’s Arexvy RSV vaccine to adults aged 50–59, broadening the addressable market for a product with proven two-season protection (Reuters)
FDA advisory panel’s recommendation against approving Blenrep is likely to delay U.S. market entry and jeopardize up to £3 billion in peak sales forecasts, straining GSK’s pipeline growth (Reuters)
Uncertainty over U.S. vaccination policy under new HHS leadership could hamper uptake of Arexvy RSV vaccine, exposing GSK to revenue volatility in its largest market (Reuters)
GSK forecasts a low single-digit decline in vaccine sales for 2025, reflecting ongoing headwinds in its largest division and pressuring overall revenue growth (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.

GlaxoSmithKline Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GlaxoSmithKline Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £GSK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Oct9
GlaxoSmithKline
Dividend·Payment
£0.16Per share
FAQs